InnoCan Pharma Corporation

DB:IP4 Stock Report

Market Cap: €35.4m

InnoCan Pharma Past Earnings Performance

Past criteria checks 0/6

InnoCan Pharma has been growing earnings at an average annual rate of 10.5%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 85.1% per year.

Key information

10.5%

Earnings growth rate

24.0%

EPS growth rate

Pharmaceuticals Industry Growth7.3%
Revenue growth rate85.1%
Return on equity-14.6%
Net Margin-9.0%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How InnoCan Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:IP4 Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2429-3262
30 Jun 2424-4232
31 Mar 2419-5192
31 Dec 2314-5142
30 Sep 2310-5112
30 Jun 237-391
31 Mar 234-472
31 Dec 223-472
30 Sep 221-371
30 Jun 221-771
31 Mar 220-661
31 Dec 210-1061
30 Sep 210-1652
30 Jun 210-1442
31 Mar 210-1442
31 Dec 200-1032
30 Sep 200-331
30 Jun 200-541
31 Mar 200-331
31 Dec 190-330
30 Sep 190-631

Quality Earnings: IP4 is currently unprofitable.

Growing Profit Margin: IP4 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: IP4 is unprofitable, but has reduced losses over the past 5 years at a rate of 10.5% per year.

Accelerating Growth: Unable to compare IP4's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IP4 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (25.4%).


Return on Equity

High ROE: IP4 has a negative Return on Equity (-14.55%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 11:33
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

InnoCan Pharma Corporation is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution